Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

Table 4 Indirect comparison of hazard ratios for risk of relapse

	PP	Paliperidone ER	PP placebo	Paliperidone ER placebo
	(n= 193)	(n= 104)	(n= 192)	(n= 101)
Subjects with events, n (%)	32 (17)	23 (22)	90 (47)	52 (51)
Hazard ratio (95% CI)^a	2.52 (1.46 to 4.35)		2.25 (1.59 to 3.18)

^aHazard ratios reflect paliperidone ER/PP for active treatments and placebo treatments, respectively. CI confidence interval, ER extended release, PP paliperidone palmitate.

ISSN: 1744-859X